Exhibit 10.18.1
Confidential Materials omitted and filed separately with the Securities
and Exchange Commission. Asterisks denote omissions.
AGREEMENT
This agreement is made by and between
IDENIX PHARMACEUTICALS, INC. a corporation organized and existing under
the laws of the State of Delaware, having its principal offices located at
000 XxxxxxxxxXxxx Xxxxx, Xxxxxxxxx, XX 00000 represented by its legal
representative Xx. Xxxx-Xxxxxx Xxxxxxxxxx (hereinafter referred to as
"Idenix")
and
IDENIX SARL, a corporation organized and existing under the laws of France,
having registered offices in Immueuble "La Vigie" 000 xxx Xxxx Xxxx, 00000
Xxxxxxxxxxx, Xxxxxx, represented by its legal representative Xx. Xxxx-Xxxx
Xxxxxxx (hereinafter referred to as "Idenix SARL")
and
UNIVERSITA' DELGI STUDI DI CAGLIARI, having a principal place of business at
Cittadella Universitaria, SS 554 XX 0.0, 00000 Xxxxxxxxxx, Xxxxxxxx, Xxxxx,
represented by the Chancellor Xxxx. Xxxxxxxx Xxxxxxxxx (hereinafter referred to
as the "University")
whereas
a) on 4th of January 1999 the University and Idenix SARL, this last on behalf
and for the benefit of Idenix, entered into an agreement entitled "Co-operative
Antiviral Research Activity Agreement" (hereinafter referred to as "Co-operative
Agreement") aimed at performing a joined research activity in the antiviral
substances field;
b) in accordance with the Co-operative Agreement, on 14 December 2000 the
University and Idenix entered into a license agreement (hereinafter "License
Agreement") according to which the University grants to Idenix the exclusive
license for the exploitation, whether direct or indirect, of the results
obtained and that will be obtained from the performance of the activity
indicated under the previous point;
c) the above mentioned Co-operative Agreement and License Agreement have
been initially amended on 10 April 2002;
d) said agreements have been further amended with the deed undersigned by the
parties on May 8, 2003, also in consideration of the transactions at that time
pending between Idenix and Novartis Pharma AG for the acquisition, by this last,
of the majority of the shareholding of Idenix (the amendments indicated in this
point have become effective on May 8, 2003, following
to the occurred execution of a "Development, License and Commercialization
Agreement" and of a "Manufacturing and Supply Agreement" by and among Idenix,
Idenix (Cayman) Limited and Novartis);
e) in compliance with the provision set forth under art. 9.1 of the
Co-operative Agreement, art. 3 of the License Agreement states that Idenix
shall pay to the University earned royalties at a rate equal to
(i) [**]% of Net Sales in case of direct exploitation of the results
obtained from the performance of the research activity in accordance
with Co-operative Agreement;
(ii) [**]% of Sublicense Payments or Royalties in case of
sublicense of the Intellectual Property Rights
now, therefore, in consideration of the premises and the mutual covenants herein
contained, Idenix, Idenix SARL and the University agree as follows:
1. The premises shall represent an integral and substantial part of this
agreement.
2. Also in consideration of the relevance of the results that the parties
are obtaining from the joined research carried out, the royalty rate
payable by Idenix or any of its subsidiaries indicated under art. 9.1 of
the Co-operative Agreement and art. 3 of the License Agreement shall be
increased from [**]% to [**]%.
The parties hereby furthermore agree that such an increased royalty rate shall
apply to technology and other property that becomes initially subject to patent
applications (including US provisional applications) which constitute the parent
case filed on or after 14 May 2003.
For the purposes of this point 2, the date of the first filing of each parent
case patent application shall be considered (not the date of the corresponding
foreign extensions).
The parties hereby agree that the rate of royalty will be exclusively determined
by reference to the date of filing of the parent application.
3. The percentage defined under previous point 2 shall be calculated on Net
Sales whether performed directly by Idenix or by a sublicense. As regards to
patent applications, including US provisional patent applications, filed before
14 May 2003, from the execution date of the present agreement, the [**]% royalty
shall as well be calculated on Net Sales whether performed directly by Idenix or
by a sublicense. For the purpose of this section 3, the definition of "Net
Sales" provided under section 1.10 of the License Agreement shall apply.
3.1. Idenix shall provide the University of Cagliari with the right of a yearly
audit to check the correct undertakings and fulfillments of any obligations of
the Cooperative Agreement, of the License and relevant amendments.
4. The present document represents an amendment to art. 9.1 of the Co-operative
Agreement and to art. 3 of the License Agreement that, with reference to any
other provision, shall entirely apply in the current version (and with the
possible amendments that might be brought in the future) to the relationships
existing among the parties (and with the possible amendments brought in the
future). The parties however agree that in any case in which it is provided to
the University the right to grant non exclusive licenses, this has to be
understood both as non exclusive and exclusive license right.
5. The parties hereby agree that the patents filed by or on behalf of Idenix or
Novartis in order to protect the results of the activity performed in pursuance
of the Cooperative Agreement, are therefore deemed subject to the terms of the
License Agreement and shall be included in the Annex to the License Agreement. A
copy of Annex A as it is currently constituted is attached hereto and made a
part of the License Agreement. The Annex A attached hereto supercedes in its
entirety the Annex A referred to in the amendment dated 10 April 2002 of the
License Agreement and Co-operative Agreement. In the future, Idenix will provide
to include in such Annex the new patent applications concerning results obtained
within the Cooperative Activity, providing the University with a quarterly
communication of such Annex including the new patent applications which updated
Annex A will be deemed to be agreed to by the University.
In the Annex A attached hereto are not included the following patents: US patent
application No. 60/626184 (Sommadossi) and US patent application No. 60/326192
(Sommadossi) that were un-correctly inserted in previous Annex A of the License
Agreement, since they are not part of the Co-operative Antiviral Research
Activity Agreement due to the fact that Xxxxxxxxx Xxxxx XX Xxxxx did not
contributed, even partially, to the achievement of the relevant inventions.
6. In order to clarify the provisions set forth in the agreement undersigned by
the parties on 8 May 2003 mentioned in the premises, the parties recognize and
accept that the rights and the obligations, stated upon the Dipartimento di
Scienze e Tecnologie Biomediche by the Co-operative Agreement and by the License
Agreement (as finally amended on 8 may 2003) shall be considered exclusively
referred to the Sezione di Microbiologia e Virologia Generale e Biotecnologie
Microbioche, directed by Xxxx. Xx Xxxxx.
7. The parties hereto agree that the initial term of the Co-operative Agreement,
as amended, shall expire on January 22, 2007 and that the Co-operative Agreement
may be renewed for additional four year periods by mutual consent of the parties
expressed in writing at least 30 days prior to the expiration of the then
current term.
8. This agreement is drafted in English, and for the sole purpose of allowing
the University to better comprehend the relevant content, in Italian, being
understand that in case of contrasts between the English version and the Italian
version, the English one shall prevail.
June 30, 2004
--------------------------------------
Date
/s/Xxxx Xxxxxx Sommadossi
--------------------------------------
name and appointment
IDENIX PHARMACEUTICALS, INC.
/s/Xxxx Xxxxxx Sommadossi
--------------------------------------
name and appointment
IDENIX SARL
/s/ Xxxxxxxx Mistietia
--------------------------------------
Xxxx. Xxxxxxxx Mistietia
/s/ Xxxxx XxXxxxx
--------------------------------------
Xxxx. Xxxxx XxXxxxx
EXHIBIT A
PATENT / ISSUE /
TITLE FILING SERIAL PUBLICATION PUB.
& DOCKET NAME COUNTRY OWNER INVENTORS DATE NUMBER NUMBER DATE STATUS
------------- ------- ----- --------- ---- ------ ------ ---- ------
[**] [**] [**] [**] [**] [**] [**]
X.
XxXxxxx,
XXX0000 U.S. USC IDXINC JP. 5/26/01 09/863,816 2003/0060400 03/27/03 Allowed
Sommadossi
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
X.
XxXxxxx,
XXX0000 CON 3 U.S. USC IDXINC JP. 6/20/03 10/602,692 2004/0097462 05/20/04 Published
Sommadossi
X.
XxXxxxx,
XXX0000 DIV U.S. USC IDXINC JP. 6/20/03 10/602,693 2004/0063622 04/01/04 Published
Sommadossi
[**] [**] [**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
PATENT / ISSUE /
TITLE FILING SERIAL PUBLICATION PUB.
& DOCKET NAME COUNTRY OWNER INVENTORS DATE NUMBER NUMBER DATE STATUS
------------- ------- ----- --------- ---- ------ ------ ---- ------
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
IDX1007 U.S. USC P. 5/23/01 9/864,078 2003/0050229 3/13/03 Allowed
IDXINC XxXxxxx,
XX.
Sommadossi
IDX1007CON1 6/20/03 10/602,691 2004/0097461 05/20/04 Published
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
PATENT / ISSUE /
TITLE FILING SERIAL PUBLICATION PUB.
& DOCKET NAME COUNTRY OWNER INVENTORS DATE NUMBER NUMBER DATE STATUS
------------- ------- ----- --------- ---- ------ ------ ---- ------
[**] [**] [**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**] [**] [**]
X-X
Xxxxxxxxxx
IDX1009CON1 US CON USC IDXINC P XxXxxxx 1/24/03 10/350,772 2003/0225114 12/04/03 Published
M Artico
M Xxxxxx
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
PATENT / ISSUE /
TITLE FILING SERIAL PUBLICATION PUB.
& DOCKET NAME COUNTRY OWNER INVENTORS DATE NUMBER NUMBER DATE STATUS
------------- ------- ----- --------- ---- ------ ------ ---- ------
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
IDX 1031
2'-C-Methyl-3'-
O-L-Valine
Ester JP
Ribofuranosyl U.S. USC. Sommadossi 6/27/03 10/607,909 2004/0077587 04/22/04 Published
Cytidine for IDXINC P La
Treatment of Colla
Flaviviridae
Infections
(NM283)
[**] [**] [**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**] [**]
[**]
[**]
[**]
[**]
[**]
[**]
